BioCryst Fell 19% in a Week — an Oral Rival Just Matched Orladeyo's Edge

BioCryst Pharmaceuticals has now closed lower five straight sessions, down roughly 19% over that stretch to about $8 a share, with the worst single day coming after an event that has nothing to do with its own results. The stock that routinely beat expectations through 2026 was hit last week by a competitor's trial data — and a sell-side note reported to call the near-term outlook "challenging" poured fuel on the slide. The natural retail instinct is to assume the business broke. It hasn't, at least not yet. What happened instead is trickier: the competitive threat that was always the bear case finally produced a number, and the market treated it as the franchise ending.

The number belongs to Pharvaris, a much smaller rival. On September 8 it reported topline results from CHAPTER-3, its pivotal Phase 3 study of deucrictibant as a once-daily oral tablet to prevent hereditary angioedema (HAE) attacks — the swelling disorder where BioCryst's Orladeyo has built its franchise. The drug cut monthly attacks by 83% versus placebo at 24 weeks and hit every secondary endpoint, and Pharvaris plans to file for prophylactic approval in the first half of 2027.

What matters is not just the efficacy number but the route of administration. Orladeyo became the category leader largely because it is the only oral, once-daily prophylactic for HAE, an edge over older injected treatments that require needles several times a week. Deucrictibant is also an oral, once-daily tablet — it attacks the exact axis Orladeyo owns. That makes this genuinely competitive, not narrative. A second, bigger shadow hangs further out: Intellia's one-time gene therapy cut HAE attacks by 87% in its own Phase 3 trial earlier this year, a potential functional cure that would eventually threaten the entire chronic-medication model.

That is the bear case, and it is real. But here is where the story demands a dose of JR-style scrutiny before you conclude the market is right. Competition existing is not the same as the moat being breached. Look at what the selloff is happening against. In the quarter reported August 5, BioCryst posted total revenue of $218.3 million, up 45%, with Orladeyo at $158.2 million; it posted about $113 million in non-GAAP operating profit, maintained its Orladeyo revenue guidance of $625 million to $645 million for the year, and raised its total revenue guidance to $690 million to $715 million. Yesterday's concern is years away from showing up in any of these numbers — deucrictibant won't launch until roughly 2027, and even then patients must choose to switch, payers must agree, and the tolerability profile must hold against an established drug.

Now price it. BioCryst carries a market capitalization of about $2.1 billion — roughly 2.3 times trailing sales of about $940 million — running about 98% gross margins with positive operating cash flow of more than $370 million over the last twelve months. Forget the stock's forward price-to-earnings ratio — it is a meaningless artifact of one-time acquisition charges from the purchase of Astria Therapeutics, which gave BioCryst its own injectable HAE candidate, navenibart. Measured against sales and cash flow, this is not a rich valuation for a business that is still growing close to double digits organically and is the rare biotech that is actually generating cash.

The honest reading is that the market has arguably baked a permanently capped Orladeyo into the price — a discount for a threat that is real but not yet present. That is the argument for treating this as an overdone selloff. The counterargument, and it is a fair one, is that HAE is a small, concentrated market where a plurality of patients may genuinely prefer an oral rival, and a cautionary note from a firm that had carried an Outperform rating on the shares for most of the year suggests even its old supporters now see the path getting rougher. This is not a clean contrarian buy, because the moat genuinely is under new stress rather than merely feared to be. But the burden of proof has shifted: to argue the business deserves its recent loss, you now have to argue the franchise is contracting, and nothing in the current numbers shows that.

The one variable that resolves this is whether Orladeyo's U.S. prescription growth holds as deucrictibant approaches and, eventually, launches. If that trajectory keeps climbing, this looks like selling exhaustion on a still-growing cash machine; if it begins to flatten as patients vote for the newcomer, the market was right all along. BioCryst doesn't need a miracle to justify the current price — it needs the recent damage to be ahead of the actual competition. So far, that's the bet the selloff is offering.